TD Cowen maintains Buy ratings on Establishment Labs and Rocket Lab
TD Cowen kept Buy ratings on Establishment Labs with a $117 target and on Rocket Lab with a $90 target. The implied upside is 102.1% and 52.1% from the October 14 closes.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Analysts at TD Cowen maintained their Buy recommendation on Establishment Labs Hldgs with a price target of $117. That level implies an upside of 102.1% from the October 14 close of $57.88. According to the note, the company is nearing FDA approval for its breast reconstruction products, which could open a market comparable in size to its existing augmentation business. The flagship Motiva product has earned positive feedback from plastic surgeons.
For Rocket Lab, TD Cowen also kept its Buy rating, with a $90 target. That implies a 52.1% gain from the October 14 close of $59.18. The analysts point to the company's strong standing in the space industry and its record of regular launches for private and public customers, even with the delay of the Neutron rocket.
why it matters
For investors, such estimates offer a read on sentiment toward the stocks, but analyst price targets do not guarantee where shares will trade, so they should be weighed against each investor's own view of risk.
tags
instruments
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗